CCO Cintia Piccina terminated by redundancy; severance $473,800

Adaptimmune Therapeutics PLC

Chief Commercial Officer Cintia Piccina employment terminated effective August 8, 2025 due to redundancy.
Severance payment of $473,800 (12 months base salary) paid in lump sum after effective date.
Vested options over 1,125,648 ordinary shares exercisable until January 30, 2032; other vested options exercisable for 12 months post-separation.
Separation agreement includes full release of claims and mutual non-disparagement.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.